logo-loader
OraSure Technologies

OraSure Technologies posts 4Q earnings beat, but stock tumbles on lower guidance

The company said it expects a first quarter loss of $0.07 to $0.06 per share on revenue of $29.0 million to $30.5 million.

Vials of blood samples
The company makes the OraQuick Advance HIV test, which is widely used in hospitals and doctor's offices

OraSure Technologies Inc (NASDAQ:OSUR) stock tumbled Thursday after the maker of diagnostic test kits posted fourth-quarter earnings that beat estimates but guided lower.

Investors sent shares of the Bethlehem, Pennsylvania, company reeling 14.5% to $10.95 in pre-market trade.

For the quarter ended June 2018, OraSure Technologies posted earnings of $0.20 per share on revenue of $50.2 million. The consensus earnings estimate was $0.11 per share on revenue of $47.5 million. Revenue fell 3.4% compared with the same quarter a year ago.

READ: Hemispherx BioPharma launches $8M rights issue to fund cancer drug trials

Looking ahead, the company said it expects a first-quarter loss of $0.07 to $0.06 per share on revenue of $29.0 million to $30.5 million. The current consensus estimate is for earnings of $0.09 per share on revenue of $45.1 million for the quarter ending March 31, 2019.

OraSure Technologies makes oral fluid diagnostic products and specimen-collection devices in the US, Europe and internationally. The company makes the OraQuick Advance HIV test, which is widely used in hospitals and doctor's offices. OraSure also supplies oral fluid testing solutions for drugs-of-abuse testing.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: OraSure Technologies

Price: $7.22

Market: NASDAQ
Market Cap: $445.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

2 days, 10 hours ago

2 min read